Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhongyianke Bio Raises $36 Million to Expand Vaccine Portfolio

publication date: Jul 5, 2019

Zhongyianke Biotech, a Tianjin vaccine maker, raised $36 million in a Series A financing led by Shenzhen Qianhai Beizeng Asset Management. Founded in 2001, Zhongyianke has launched a flu vaccine and is conducting clinical trials on four other human vaccines: a tetravalent influenza vaccine, a tetravalent meningococcal vaccine, a rabies vaccine, and a rubella vaccine. The company holds 14 China patents. In addition to its operations in Tianjin, the company has an R&D center in Beijing and a production facility in Liaoning Province. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital